Purple Biotech (PPBT)
NASDAQ:PPBT
Want to see PPBT full AI Analyst Report?
PPBT Stock Chart & Stats
$4.87
-$0.22(-5.25%)
At close: 4:00 PM EST
$4.87
-$0.22(-5.25%)
Day’s Range― - ―
52-Week Range$2.52 - $29.00
Previous CloseN/A
Volume16.93K
Average Volume (3M)415.61K
Market Cap
$6.83M
Enterprise Value-$3.52M
Total Cash (Recent Filing)$6.43M
Total Debt (Recent Filing)$184.00K
Price to Earnings (P/E)―
Beta0.67
Next Earnings
Jul 30, 2026EPS Estimate
-0.98Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-9933.94
Shares Outstanding1,013,064
10 Day Avg. Volume296,099
30 Day Avg. Volume415,608
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-0.52
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit15.67
Enterprise Value/Ebitda0.46
Forecast
1Y Price Target
$30.00Price Target Upside516.02% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.65
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Differentiated CAPTN-3 PlatformPreclinical IM1240 data and CAPTN-3’s capping technology suggest a differentiated tri-specific approach that confines CD3 activation to tumor microenvironments. This structural advantage can expand the therapeutic window versus conventional engagers, improving clinical viability and partner interest over the next several years.
Experienced Scientific Advisory BoardAssembling clinicians and scientists experienced in T- and NK-cell biology and first-in-class engager development strengthens translational strategy, trial design and go-to-market planning. Durable benefit: higher probability of efficient clinical development and greater attractiveness to partners and investors.
Conservative Leverage ProfileLow financial leverage reduces default risk and preserves flexibility to fund R&D or negotiate partnerships without being debt-constrained. Over 2–6 months this supports strategic options for IND-enabling and early clinical spending while avoiding interest burden common in highly leveraged peers.
Bears Say
No Meaningful RevenueAs a clinical-stage biotech with no product sales, operating economics depend on partnerships or financing. Persistent material net losses mean the company must secure external funding for development, increasing dilution risk and creating execution dependence on successful trials or deal-making.
Sustained Cash BurnConsistent negative operating and free cash flow indicate ongoing funding needs to progress IND-enabling and clinical programs. This structural cash burn pressures the balance sheet and raises the odds of financing rounds or partnership transactions that can delay programs or dilute existing shareholders.
Equity Erosion And Asset ImpairmentsSharp decline in equity and a large non-cash impairment on legacy programs signal prior pipeline disappointments and reduced internal optionality. Structurally, this weakens the company’s capital base, limits self-funding capacity for new trials, and increases reliance on partners or financings to advance prioritized assets.
Purple Biotech News
PPBT FAQ
What was Purple Biotech’s price range in the past 12 months?
Purple Biotech lowest stock price was $2.52 and its highest was $29.00 in the past 12 months.
What is Purple Biotech’s market cap?
Purple Biotech’s market cap is $6.83M.
When is Purple Biotech’s upcoming earnings report date?
Purple Biotech’s upcoming earnings report date is Jul 30, 2026 which is in 49 days.
How were Purple Biotech’s earnings last quarter?
Purple Biotech released its earnings results on May 15, 2026. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.38 by $0.29.
Is Purple Biotech overvalued?
According to Wall Street analysts Purple Biotech’s price is currently Undervalued.
Does Purple Biotech pay dividends?
Purple Biotech does not currently pay dividends.
What is Purple Biotech’s EPS estimate?
Purple Biotech’s EPS estimate is -0.98.
How many shares outstanding does Purple Biotech have?
Purple Biotech has 1,013,064 shares outstanding.
What happened to Purple Biotech’s price movement after its last earnings report?
Purple Biotech reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.38. Following the earnings report the stock price went up 6.775%.
Which hedge fund is a major shareholder of Purple Biotech?
Currently, no hedge funds are holding shares in PPBT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Purple Biotech
Purple Biotech Ltd., a clinical-stage biotechnology firm based in Rehovot, Israel, is dedicated to pioneering treatments that help cancer patients, particularly in the United States, overcome tumor immune evasion and drug resistance. Its pipeline features two primary oncology assets: CM24: A monoclonal antibody designed to block carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). This candidate is undergoing Phase 1b/2 clinical trials, where it is being evaluated as a combination therapy with anti-PD-1 checkpoint inhibitors for non-small cell lung cancer and pancreatic cancer. NT219: A small molecule compound that targets insulin receptor substrate 1 and 2 (IRS1/2) as well as signal transducer and activator of transcription (STAT) pathways. NT219 is currently in Phase 1/2 clinical studies for the treatment of recurrent or metastatic solid tumors and squamous cell carcinoma of the head and neck. The company was formerly known as Kitov Pharma Ltd until its rebranding to Purple Biotech Ltd. in December 2020.
PPBT Stock 12 Month Forecast
Average Price Target
$30.00
▲(516.02% Upside)
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
1.79% Other Institutional Investors
98.21% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---